Driving Advancements in the Treatment of Multiple Myeloma with Dr. Tania Small GSK

Published: Aug. 10, 2022, 4:28 p.m.

Dr. Tania Small is the Vice President and Head of Global Oncology Medical Affairs and Chair, R&D Diversity, Equity & Inclusion Counsel at GSK. To improve clinical participation and outreach to a more diverse multiple myeloma community, GSK created the Target the Future Think Tank Challenge to find partners to meet unmet needs.

Tania explains, "This is where this whole Target the Future program stems from. It was really understanding what the needs are in the multiple myeloma community so that we get an earlier diagnosis so that we get improved access so that we get improved outcomes. What we did at GSK is we asked those questions. Then we paused and said actually the people who are best equipped to tell us is, are the patients themselves and their caregivers. And so, our goal was to take a grassroots approach to really understanding what are the key needs in this community to have the optimal outcome."

"So, we launched something called Target the Future to your point, this think tank for anyone in the community who could come up with innovative and impactful solutions to address these problems. We wanted them to let us know, and what we decided to do was fund their idea, not only fund the idea but give help to implement this idea."

"Yes, and we were extremely impressed with all three of our finalists. But this one really checked all the boxes and what they pitched was a HealthTree Equity and Diversity program. When you go through it, it really shows me an optimal model because not only did they check all of the boxes, but they were creating a real, sustainable solution within the communities that they were trying to strengthen and trying to help."

@GSK #TargettheFuture #MultipleMyeloma #HealthTreeFoundation

gsk.com

Download the transcript here

   ***************************

Interview with HealthTree Foundation

Podcast and Transcript

GSK